Provided by Tiger Fintech (Singapore) Pte. Ltd.

Fulcrum Therapeutics

6.88
+0.28004.24%
Post-market: 6.880.00000.00%16:21 EDT
Volume:1.04M
Turnover:7.13M
Market Cap:371.38M
PE:-837.90
High:7.06
Open:6.69
Low:6.31
Close:6.60
Loading ...

We're Interested To See How Fulcrum Therapeutics (NASDAQ:FULC) Uses Its Cash Hoard To Grow

Simply Wall St.
·
08 Apr

Fulcrum Therapeutics Faces Termination of Key Agreement

TIPRANKS
·
05 Mar

BRIEF-Fulcrum Therapeutics Inc Myokardia Terminates Collaboration And License Agreement With Co

Reuters
·
05 Mar

Fulcrum Therapeutics Inc - Myokardia Terminates Collaboration and License Agreement With Co

THOMSON REUTERS
·
05 Mar

Fulcrum Therapeutics Inc - Termination Effective June 26, 2025

THOMSON REUTERS
·
05 Mar

Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference

GlobeNewswire
·
05 Mar

Fulcrum Therapeutics’ Earnings Call Highlights Financial Gains

TIPRANKS
·
28 Feb

Fulcrum Therapeutics: Progress in Pociredir Trial Amidst Uncertainties and Market Challenges

TIPRANKS
·
27 Feb

Fulcrum Therapeutics Price Target Maintained With a $4.00/Share by HC Wainwright & Co.

Dow Jones
·
26 Feb

Fulcrum Therapeutics Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.
·
26 Feb

Sell Rating on Fulcrum Therapeutics Due to Uncertain Prospects and Financial Concerns

TIPRANKS
·
26 Feb

Fulcrum Therapeutics Inc (FULC) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...

GuruFocus.com
·
26 Feb

Q4 2024 Fulcrum Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
26 Feb

Fulcrum Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
25 Feb

Fulcrum Therapeutics reports Q4 EPS (31c), consensus (29c)

TIPRANKS
·
25 Feb

Fulcrum Therapeutics sees sufficient cash to fund requirements to at least 2027

TIPRANKS
·
25 Feb

Fulcrum Therapeutics Q4 GAAP EPS $(0.31) Beats $(0.32) Estimate

Benzinga
·
25 Feb

BRIEF-Fulcrum Therapeutics Q4 Basic EPS USD -0.31

Reuters
·
25 Feb

Fulcrum Therapeutics Q4 Basic EPS USD -0.31

THOMSON REUTERS
·
25 Feb

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024

GlobeNewswire
·
25 Feb